Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, ready-to-use therapeutic medicines for patients with chronic endocrine and neurological diseases. The company leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to create liquid-stable injectable formulations that improve patient convenience and ease of use. The company's commercial portfolio includes Recorlev (levoketoconazole) for endogenous hypercortisolemia in patients with Cushing's syndrome, Gvoke (glucagon) for severe hypoglycemia, and Keveyis (dichlorphenamide) for Primary Periodic Paralysis. Xeris is actively expanding its pipeline, with a key focus on advancing its once-weekly subcutaneous levothyroxine candidate, XP-8121, into Phase 3 clinical trials.